A number of other equities analysts also recently weighed in on ENDP. Mizuho reissued a buy rating and issued a $19.00 price target on shares of Endo International PLC in a report on Thursday, August 10th. ValuEngine raised Endo International PLC from a hold rating to a buy rating in a report on Monday, October 2nd.
Endo International plc (NASDAQ:ENDP) is standing on a contradictory position.
ILLEGAL ACTIVITY NOTICE: "Royal Bank Of Canada Trims Endo International PLC (ENDP) Target Price to $8.00" was reported by TrueBlueTribune and is owned by of TrueBlueTribune.
The ABR is the calculated average of the actual recommendations (strong buy, hold, sell etc.) made by the brokerage firms for the given stock. Cantor Fitzgerald released research on ENDP with a rating of "Hold" and price target of $9.00.
Endo International PLC (NASDAQ ENDP) opened at $6.69 on Thursday. These ratios are important while doing valuation of the company or the shares of the company. The stock touched 52-week High of $18.63 on 11/15/16 and 52-week Low of $5.77 on 10/27/17. The company has a market capitalization of $1,550.00, a P/E ratio of 1.43 and a beta of 0.53.
Analysts believe that the company has the potential to earn average revenue of $762.29 Million for the current quarter.
On the other hand Endo Int'l Plc (NASDAQ:ENDP) has Relative Strength Index (RSI 14) of 46.04 along with Average True Range (ATR 14) of 0.53. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.85 by $0.06. Endo International PLC had a negative net margin of 126.97% and a positive return on equity of 66.98%. This estimate is provided by 16 analysts. Endo Int'l Plc (NASDAQ:ENDP) has a market cap of $1.49 Billion and the number of outstanding shares have been calculated 223.3 Million.
TRADEMARK VIOLATION WARNING: This piece was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of United States & worldwide trademark and copyright legislation. Oppenheimer Holdings, Inc. reaffirmed a "hold" rating on shares of Endo International PLC in a research note on Sunday, July 23rd. The stock, after opening at $6.86, hit $6.69 through the close by scoring -3.46%. The shares were purchased at an average cost of $7.89 per share, with a total value of $51,285.00. Amalgamated Bank now owns 32,357 shares of the company's stock valued at $361,000 after buying an additional 619 shares in the last quarter. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.
The company now has an insider ownership of 0.5 Percent and Institutional ownership of 89.5 Percent. Amalgamated Bank boosted its stake in shares of Endo International PLC by 2.0% in the first quarter.
The counter witnessed a trading volume of 7.18 million shares versus an average volume of 6.48 million shares during last trading session. As of quarter end California State Teachers Retirement System had sold 38,095 shares trimming its stake by 9.3%. Past 5 years growth of the company observed at -2.88%, and for the next five years the analysts that follow the company are expecting its growth at -6.31%. Capstone Asset Management Co. boosted its stake in shares of Endo International PLC by 3.1% in the second quarter. Gamco Investors INC. ET AL now owns 110,500 shares of the company's stock valued at $946,000 after purchasing an additional 47,800 shares during the last quarter. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland. Following the acquisition, the chief financial officer now owns 13,729 shares in the company, valued at approximately $108,321.81. River & Mercantile Asset Management LLP boosted its holdings in shares of Endo International PLC by 116.3% in the 3rd quarter.
Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Infotek Pharmaceuticals, and Pacira Pharmaceuticals.